Organic compounds
AssigneeIntra-Cellular Therapies, Inc.
InventorsAllen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
Claims5
A method of treatment for psychotic symptoms selected from hallucinations, paranoid or bizarre delusions and disorganized speech and thinking in psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania or bipolar disorder comprising administering an effective amount of a PDE 1 inhibitor to a patient in need thereof wherein the PDE 1 inhibitor is:
- in free or salt form, including its enantiomers, diastereoisomers and racemates.
Dependencies are inferred from the claim text.